Home › Compare › EDTXF vs PLD

EDTXF vs PLD: Dividend Comparison 2026

EDTXF yields 203.25% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EDTXF wins by $124.58M in total portfolio value
10 years
EDTXF
EDTXF
● Live price
203.25%
Share price
$0.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$131.09M
Annual income
$66,614,308.55
Full EDTXF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — EDTXF vs PLD

📍 EDTXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEDTXFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EDTXF + PLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EDTXF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EDTXF
Annual income on $10K today (after 15% tax)
$17,276.42/yr
After 10yr DRIP, annual income (after tax)
$56,622,162.27/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, EDTXF beats the other by $52,154,191.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EDTXF + PLD for your $10,000?

EDTXF: 50%PLD: 50%
100% PLD50/50100% EDTXF
Portfolio after 10yr
$68.80M
Annual income
$35,935,372.36/yr
Blended yield
52.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

EDTXF
No analyst data
Altman Z
-75.3
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EDTXF buys
0
PLD buys
0
No recent congressional trades found for EDTXF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEDTXFPLD
Forward yield203.25% ✓3.18%
Annual dividend / share$2.00$4.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4% ✓
Portfolio after 10y$131.09M ✓$6.50M
Annual income after 10y$66,614,308.55 ✓$5,256,436.18
Total dividends collected$123.65M ✓$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: EDTXF vs PLD ($10,000, DRIP)

YearEDTXF PortfolioEDTXF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$31,025$20,325.20$11,255$555.24+$19.8K → EDTXF
2$92,131$58,933.98$13,062$1,018.59+$79.1K → EDTXF
3$262,139$163,558.41$15,903$1,926.67+$246.2K → EDTXF
4$715,413$434,925.03$20,839$3,823.32+$694.6K → EDTXF
5$1,874,812$1,109,319.79$30,464$8,166.08+$1.84M → EDTXF
6$4,722,949$2,716,900.45$52,054$19,457.30+$4.67M → EDTXF
7$11,450,101$6,396,545.74$109,886$54,188.93+$11.34M → EDTXF
8$26,744,592$14,492,983.16$304,030$186,451.18+$26.44M → EDTXF
9$60,254,103$31,637,389.98$1,166,125$840,813.32+$59.09M → EDTXF
10$131,086,199$66,614,308.55$6,504,190$5,256,436.18+$124.58M → EDTXF

EDTXF vs PLD: Complete Analysis 2026

EDTXF — Stock

Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Full EDTXF Calculator →

PLD — REIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this EDTXF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EDTXF vs SCHDEDTXF vs JEPIEDTXF vs OEDTXF vs KOEDTXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.